Kintor Pharmaceutical Ltd

Kintor Pharmaceutical Ltd

1.45
HKD
+0.12
(+9.02%)
933.80MMarket Cap
Apr 01Next Earn
Kintor Pharmaceutical Ltd
HKEX:9939
(Hong Kong Exchange)

Recent

price

1.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
- -
- -
- -
0.1
- -
- -
0.01
0.07
- -
Revenue per Share
-0.29
-0.63
-1.64
-2.36
-2.53
-2.47
-0.36
-0.44
- -
Basic EPS, GAAP
-0.36
-0.82
-1.54
-3.25
-2.63
-0.91
-0.47
-0.38
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.68
1
4.08
4.27
3.34
1.07
0.7
0.37
0.22
Book Value per Share
0.19
0.49
3.49
3.58
2.74
0.65
0.33
0.14
0.03
Tangible Book Value per Share
369
369
309
356
377
429
431
450
478
Basic Weighted Avg Shares
1
- -
- -
34
- -
- -
5
33
- -
Sales/Revenue/Turnover
-15,699.43
- -
- -
-2,439.65
- -
- -
-3,062.7
-530.27
- -
Operating Margin (%)
2
5
7
11
18
19
18
33
- -
Depreciation Expense
-108
-233
-508
-842
-954
-1,061
-155
-200
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-15,542.12
- -
- -
-2,460.04
- -
- -
-3,105.84
-612.29
- -
Profit Margin (%)
110
78
1,251
1,306
1,190
248
5
-72
-135
Working Capital
25
2
135
150
183
136
20
1
- -
LT Debt
252
370
1,508
1,655
1,495
458
294
183
109
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-74.86
-54.14
-53.25
-60.59
-108.62
-41.29
-83.96
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
87
86
134
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
438
489
489
Market Capitalization
603
861
808

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
63
55
48
Cash, Cash Equivalents & STI
53
33
31
Accounts Receivable, Net
- -
3
3
Inventories
3
12
11
Total Current Liabilities
143
128
183
Payables & Accruals
- -
- -
- -
ST Debt
87
86
134
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-28.6%
-37.91%
Free Cash Flow
- -
0.77%
-15.08%
Net Income, GAAP
- -
6.73%
28.86%
Sales/Revenue/Turnover
- -
- -
553.64%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5
2025
- -
- -
33
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.36
2025
- -
- -
-0.44
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Kintor Pharmaceutical Limited (9939.HK) is a clinical-stage biopharmaceutical company that develops innovative small-molecule and biologic drugs targeting dermatology and oncology indications with substantial unmet medical needs, particularly androgen receptor-related diseases such as alopecia, acne, prostate cancer and liver cancer. Founded in 2009 and headquartered in Suzhou Industrial Park, Suzhou, China, the company offers a diverse pipeline including KX-826 (pyrilutamide), a topical androgen receptor antagonist in phase III trials for androgenetic alopecia (AGA) and acne vulgaris, now commercialized over-the-counter as Koshiné hair loss treatment generating first revenues; GT20029, a topical AR-PROTAC compound in phase II for AGA and acne; KT-939 (oximidol), a functional raw material for skin whitening and freckle-removing cosmetics launched commercially; Proxalutamide, a second-generation AR antagonist for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors; GT90001 (ALK-1 antibody), an anti-angiogenesis biologic for hepatocellular carcinoma (HCC) and solid tumors; Detorsertib (mTOR inhibitor) for breast, prostate and HCC; Hedgehog/SMO inhibitor for blood cancers; and preclinical programs in ALK-1/VEGF dual-target antibody and c-Myc inhibitors. Kintor operates primarily in China with global patent protections exceeding 110 and a GMP-compliant manufacturing facility in Suzhou spanning 20,000 square meters. Recent developments include a strategic pivot from oncology to dermatology and cosmetics amid cash constraints, with R&D spending dropping 91.7% to 78.1 million yuan in 2024 focused on core assets KX-826 and GT20029; commercialization of six over-the-counter products including Koshiné, acne cream, whitening essence and lotion via platforms like Tmall, JD.com, Douyin and Amazon, yielding 5 million yuan revenue in 2024; positive phase III enrollment completion for KX-826 AGA tincture (July 2025), phase II primary endpoint achievement for GT20029 acne gel (August 2025), long-term safety trial completion for KT-939 (September 2025), and KX-826/minoxidil combination study meeting primary endpoint (May 2025); alongside oncology trial advancements like phase II enrollment for AR-PROTAC (June 2024) while de-emphasizing higher-cost cancer pipelines.

Company News

  • Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

  • Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

  • Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA